0
Upcoming Allied Market Research
2023
P2x7 Receptor Antagonists Market

P2X7 Receptor Antagonists Market: Global Opportunity Analysis and Industry Forecast, 2023-2030 Market

Report Code: A10362
Pages: NA
Apr 2023 | 1303 Views
Author(s) : NA
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the P2x7 Receptor Antagonists Market

Request Now !

P2X7 Receptor Antagonists Market Outlook – 2027

The P2X7 receptor is an ATP-gated, non-selective cation channel associated with the number of inflammatory diseases.  P2X7 receptor antagonists is a therapeutic agents.  Opioid medications widely used for pain management. Therefore, approval and launch of a non-addictive pain management option is expected to be a breakthrough in this product space, P2X7 ion channel has been directly linked to major depression and animal studies have shown that antagonism of P2X7 with centrally penetrate antagonists resulted in antidepressant like activities in animal models. Therefore, inflammation, pain indications, mood disorders, and depression are the potential areas among others where, P2X7 is involved, and its antagonism can modify disease therapy. Various research studies activate the P2X7 channels due to release of pro-inflammatory cytokines IL-1b and IL-18. As adenosine triphosphate (ATP) has lowest affinity for P2X7 among all other purinergic ion channels (P2X4, P2X3, and others), extracellular ATP rarely activates P2X7 channel. P2X7 receptor antagonists have significant therapeutic potential, as P2X7 receptors have been found to be associated with regulation of inflammation, and all immune cell type’s lymphocytes, macrophages, monocytes, and others express P2X7.

Recently there is no P2X7 receptor antagonist available in the market. P2X7 is an ideal drug target as antagonism of P2X7 channel would not cause any serious side effects, as antagonism will only start when the channel is activated by high ATP concentrations, believed to happen during pathology of neuroinflammatory Antagonism of P2X7 channel does not lead to serious side effects, as antagonism will only start when the channel is activated by high ATP concentrations, believed to happen during pathology of neuroinflammatory disorders of the Central Nervous System (CNS) such as stroke, epilepsy, multiple sclerosis, chronic neurodegenerative, and neuropsychiatric diseases. Such scenario is expected to boost growth of the global P2X7 receptor antagonist market growth over the forecast period.

COVID-19 Scenario Analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

The ongoing outbreak of COVID-19pamnndemic impacted the P2x7 receptor antagonists market. Due to the temporarily shutting down of industries, the drug product not been manufacturing by manufacturer and researcher. It affect the preclinical and clinical studies of P2x7 receptor antagonist’s drug product which is hinder the growth of P2x7 receptor antagonists market.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis:

Globally, North America Expected to contribute largest market share due to the presence of large number of research and development center, availability of FDA approved product, and increasing number of manufacturer. Whereas Asia-Pacific trying to develop market growth rate attributed to rising demand  for antagonist drug product and increasing development in R&D, etc. 

Drug manufacturers are still trying advancing the P2X7 antagonist drug class by introducing innovative drugs such as “AKP-23494954/RQ-00466479” are expected to drive the P2x7 receptor antagonists market  growth. Moreover, increasing diseases associated with Central Nervous System (CNS) such as stroke, epilepsy, multiple sclerosis, chronic neurodegenerative, and neuropsychiatric diseases, robust pipeline of P2X7 receptor antagonists, Increasing R&D activities these factors are expected to develop global P2X7 receptor antagonist market growth. However the factor such as presence of low number of candidates in the pipeline compared to other conditions such as cancer, is retrain the P2x7 receptor antagonists market growth.

New product launches to flourish the market:

Manufacturers have been focusing on producing new products for specific applications as there are varying demands based on the utilization. Leading market players have determined how improved accuracy can be influential in many applications. In 2019, AstraZeneca Plc., has introduce “Purinergic receptor 2X, ligand-gated ion channel 7” P2X7 antagonist which provide help for preclinical research to explore and validate novel disease biology. In 2019, AstraZeneca Plc., has also launched another new drug product such as “AZ11657312” is a potent antagonist of the rat P2X7 receptor with a pA2 for inhibition of agonist-stimulated ethidium bromide release of 7.8 (15nM) in HEK cells stating the recombinant rat P2X7 receptor. Treatment of rats with AZ11657312, resulted in a reduction in mechanical hyperalgesia and disease severity in the streptococcal cell wall model of arthritis, and a delay in the adjuvant-induced arthritis model. Potency of AZ11657312 is ~50x lower at the human P2X7 receptor [pA2 of 6.1 (794nM)], so in vitro studies using human cells or tissues would require higher concentrations. In 2018, “Evotech” get a USFDA approval for phase I studies for P2X7 receptor antagonist. Similarly “GlaxoSmithKline Plc's” P2X7 “GSK1482160” drug product is still in phase 1 clinical trials. “Asahi Kasei” and “RaQualia Pharma” trying to introduce new product in the market such as AKP-23494954/RQ-00466479, but still in phase 2 studies.

Key benefits of the report:

  • This study presents the analytical depiction of the global P2x7 receptor antagonists market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the P2x7 receptor antagonists’ market share.
  • The current market is quantitatively analyzed to highlight the global P2x7 receptor antagonists market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed global P2x7 receptor antagonists market analysis based on competitive intensity and how the competition will take shape in coming years. 

Questions answered in the P2x7 Receptor Antagonists Market research report:

  • Who are the leading market players active in the P2x7 receptor antagonists market?
  • What are the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that will help in taking further strategic steps?

P2X7 Receptor Antagonists Market: Global Opportunity Analysis and Industry Forecast, 2020–2027 Report Highlights

Aspects Details
By Drug  Product
  • AKP-23494954/RQ-00466479
  • EVT 401
  • GSK1482160
  • JNJ-55308942
  • JNJ-54175446
  • Others (e.g.- AZ11657312)
By Application
  • Central Nervous System Disorders
  • Immunological Disorders
  • Others
By End User
  • Hospital
  • Ambulatory surgical center
  • Pharmaceutical and biotechnology companies
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players GlaxoSmithKline Plc, Johnson and Johnson, AstraZeneca Plc., RaQualia Pharma, Evotec AG, Asahi Kasei Corporation, Pfizer
 

Loading Table Of Content...


 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
P2x7 Receptor Antagonists Market

Start reading.
This Report and over 19,950+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers